Compare · GILD vs RXRX
GILD vs RXRX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Recursion Pharmaceuticals Inc. (RXRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and RXRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $195.13B, about 87.6x RXRX ($2.23B).
- Over the past year, GILD is up 27.2% and RXRX is down 40.8% - GILD leads by 67.9 points.
- RXRX has been more active in the news (13 items in the past 4 weeks vs 6 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 10 for RXRX).
- Company
- Gilead Sciences Inc.
- Recursion Pharmaceuticals Inc.
- Price
- $156.22-0.76%
- $3.46-16.63%
- Market cap
- $195.13B
- $2.23B
- 1M return
- +3.48%
- -2.54%
- 1Y return
- +27.19%
- -40.75%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 6
- 13
- Recent ratings
- 25
- 10
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Latest GILD
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
Latest RXRX
- SEC Form 424B5 filed by Recursion Pharmaceuticals Inc.
- SEC Form 8-K filed by Recursion Pharmaceuticals Inc.
- Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
- Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
- SEC Form 424B5 filed by Recursion Pharmaceuticals Inc.
- Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
- SEC Form 4 filed by Recursion Pharmaceuticals Inc.
- SEC Form 4 filed by Recursion Pharmaceuticals Inc.
- SEC Form 144 filed by Recursion Pharmaceuticals Inc.
- Director Dar Zavain was granted 4,607 shares, increasing direct ownership by 2% to 245,371 units (SEC Form 4)